Antibody data
- Antibody Data
- Antigen structure
- References [2]
- Comments [0]
- Validations
- Western blot [2]
- Immunohistochemistry [1]
- Other assay [2]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PA5-23341 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- REG3A Polyclonal Antibody
- Antibody type
- Polyclonal
- Antigen
- Other
- Reactivity
- Human
- Host
- Rabbit
- Isotype
- IgG
- Vial size
- 100 µg
- Concentration
- 1 mg/mL
- Storage
- -20° C, Avoid Freeze/Thaw Cycles
Submitted references Human intestinal bitter taste receptors regulate innate immune responses and metabolic regulators in obesity.
Preclinical PET imaging of HIP/PAP using 1'-(18)F-fluoroethyl-β-D-lactose.
Liszt KI, Wang Q, Farhadipour M, Segers A, Thijs T, Nys L, Deleus E, Van der Schueren B, Gerner C, Neuditschko B, Ceulemans LJ, Lannoo M, Tack J, Depoortere I
The Journal of clinical investigation 2022 Feb 1;132(3)
The Journal of clinical investigation 2022 Feb 1;132(3)
Preclinical PET imaging of HIP/PAP using 1'-(18)F-fluoroethyl-β-D-lactose.
Yao S, Luo Y, Zhang Z, Hu G, Zhu Z, Li F
Oncotarget 2017 Sep 26;8(43):75162-75173
Oncotarget 2017 Sep 26;8(43):75162-75173
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis of REG3A in Human intestine lysate using a REG3A polyclonal antibody (Product # PA5-23341) at a 2 µg/mL concentration.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis of REG3A in human intestine lysate. Samples were incubated in REG3A polyclonal antibody (Product # PA5-23341) using a dilution of 2 µg/mL followed by a goat anti-rabbit Ig HRP secondary antibody. PicoTect ECL substrate solution was used for this test.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemical analysis of REG3A in Human intestine. Samples were incubated in REG3A polyclonal antibody (Product # PA5-23341) using a dilution of 2.5 µg/mL followed by a peroxidase-conjugate and DAB chromogen.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 6 H&E (A&B) staining and IHC (C&D) of HIP/PAP in T3M4 and SK-BR-3 tumor tissues. Western blot analysis of HIP/PAP expression in T3M4 and SK-BR-3 tumor cells (E) .
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 4 Role of TAS2R43 in the effect on E . coli growth of CSNs from patients with obesity coli growth of CSNs from patients with obesity stimulated with bitter compounds. ( A ) E . coli CFU following treatment with the supernatant of obese patients' jejunal crypts ( n = 5-14) stimulated for 30 minutes with bitter compounds (compound-CSN) or Krebs (Krebs-CSN). Crypt-independent effects of bitter agonists are shown as well (bacteriostatic control). All results are expressed as the percentage of Krebs-CSN with or without vehicle. Compounds were grouped by their TAS2R activation profile: generalists (>5 TAS2Rs); intermediates (3 or 4 TAS2Rs), and specialists (1 or 2 TAS2Rs). Test concentrations and abbreviations are given in Table 1 . ( B ) Western blots showing expression of alpha-defensin 5 or REG3A in lysates from crypts from obese individuals. Crypts were treated for 30 minutes with bitter agonists or Krebs. Vertical line indicates that the lanes were run on the same gel but were noncontiguous. Summary of Western blot analyses for the effect on ( C ) alpha-defensin 5 or ( D ) REG3A protein expression ( n = 6-8). ( E and F ) Effect of TAS2R43 deletion/amino acid polymorphisms. ( E ) Effect on E . coli growth of the supernatant of crypts from TAS2R43 + and TAS2R43 - patients with obesity. Crypts were stimulated for 30 minutes with the TAS2R43 agonists aloin (30 muM, n = 11 TAS2R43 + , n = 4 TAS2R43 - ); quinine (0.1 mM, n = 4 TAS2R43 + , n = 2 TAS2R43 - ); or DB (0.1 mM, n =